Monoclonal antibody probes for p21(WAF1/CIP1) and the INK4 family of cyclin-dependent kinase inhibitors

Hybridoma

Volumn 19, Issue 1, 2000, Pages 63-72

  Thullberg, Minna ^a   Welcker, Markus ^a   Bartkova, Jirina ^a   Kjerulff, Anne Arnt ^a   Lukas, Jiri ^a   Högberg, Johan ^b,c   Bartek, Jiri ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b KAROLINSKA INSTITUTE   (Sweden)

^c NATIONAL INSTITUTE FOR WORKING LIFE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; EPITOPE; MONOCLONAL ANTIBODY; PROTEIN P15; PROTEIN P16; PROTEIN P21;

ANIMAL CELL; ANTIBODY SPECIFICITY; ARTICLE; CELL CYCLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FUNCTION; GENE INACTIVATION; GENE LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR PROBE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASES; CYCLINS; ENZYME INHIBITORS; HUMANS; MICE; MOLECULAR PROBES; MULTIGENE FAMILY; ORGAN SPECIFICITY; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 0034032077     PISSN: 0272457X     EISSN: None     Source Type: Journal    
DOI: 10.1089/027245700315806     Document Type: Article

References (37)

1. Morgan DO: Principles of CDK regulation. Nature 1995;374:131-134.
2. Guan K-L, Jenkins CW, Li Y, Nichols MA, Wu X, O'Keefe CL, Matera GA, and Xiong Y: Growth suppression by p18, a p16INK4/MTS1 and p14INK4B/MTS2-related CDk6 inhibitor, correlates with wild-type pRb function. Genes Dev 1994;8:2939-2952.
3. Pines J: Cyclins and cyclin-dependent kinases: A biochemical view. Biochem J 1995;308:697-711.
4. Lees E: Cyclin dependent kinase regulation. Curr Opin Cell Biol 1995;7:773-780.
5. Serrano M, Hannon GJ, and Beach D: A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/cdk4. Nature 1993;366:704-707.
6. ink4b is a potential effector of cell cycle arrest mediated by TGF-β. Nature 1994;371:257-260.
7. Hirai H, Roussel MF, Kato J, Ashmun RA, and Sherr CJ: Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases cdk4 and cdk6. Mol Cell Biol 1995;5:2672-2681.
8. Chan FKM, Zhang J, Cheng L, Shapiro DN, and Winoto A: Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16ink4. Mol Cell Biol 1995;15:2682-2688.
9. Sherr CJ, and Roberts MJ: CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501-1512.
10. Chen J, Jackson PK, Kirschner MW, and Dutta A: Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature 1995;374:386-388.
11. Luo Y, Hurwitz J, and Massague J: Cell-cycle inhibition by independent CDK and PCNA binding domains in p21CIP1. Nature 1995;375:159-161.
12. Hara E, Smith R, Parry D, Tahara H, Stone S, and Peters G: Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biol 1996;16:859-867.
13. Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, and Hannon GJ: Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 1995;377:552-557.
14. Chellappan SP, Giordano A, and Fisher PB: Role of cyclin-dependent kinases and their inhibitors in cellular differentiation and development. Curr Top Microbiol Immunol 1998227:57-103.
15. Bartek J, Bartkova J, and Lukas J: The retinoblastom a protein pathway in cell cycle control and cancer. Exp Cell Res 1997;237:1-6.
16. Lapointe J, Lachance Y, Labrie Y, and Labrie C: A p18 mutant defective in CDK6 binding in human breast cancer cells. Cancer Res 1996;56:4586-4589.
17. Miller CW, Yeon C, Aslo A, Mendoza S, Aytac U, and Koeffler HP: The p19INK4D cyclin dependent kinase inhibitor gene is altered in osteosarcoma. Oncogene 1997;15:231-235.
18. Glendening JM, Flores JF, Walker GJ, Stone S, Albino AP, and Fountain JW: Homozygous loss of the p15INK4B gene (and not the p16INK4A gene) during tumor progression in a sporadic melanoma patient. Cancer Res 1995;55:5531-5535.
19. Nakayama K, and Nakayama K: Cip/Kip cyclin-dependent kinase inhibitors:brakes of the cell cycle engine during development. BioEssays 1998;20:1020-1029.
20. Fero ML, Randel E, Gurley KE, Roberts JM, and Kemp CJ: The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 1998;396:177-180.
21. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger I, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI, and Slingerland JM: Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer. Nat Med 1997;3:227-230.
22. Zhang P, Liegeois NJ, Wong C, Finegold M, Hou H, Thompson JC, Silverman A, Harper JW, DePinho RA, and Elledge SJ: Altered cell differentiation and proliferation in mice lacking p57KIP2 indicated a role in Beckwith-Wiedemann syndrome. Nature 1997;387:151-158.
23. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer E, Kinzler K W, and Vogelstein B: W AF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-825.
24. Vidal MJ, Loganzo F, de Oliveira AR, Hayward NK, and Albino AP: Mutations and defective expression of the WAF1 p21 tumour-suppressor gene in malignant melanomas. Melanoma Res 1995;5:243-250.
25. Lukas C, Jensen SS, Bartkova J, Lukas J, and Bartek J: Immunochemical analysis of the D-type cyclin-dependent kinases cdk4 and cdk6, using a series of monoclonal antibodies. Hybridoma 1999;18:225-234.
26. Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, Peters G, and Bartek J: Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 1995;375:503-506.
27. Bartkova J, Lukas J, Strauss M, and Bartek J: Cyclin D3: Requirement for G1/S transition and high abundance in quiscent tissues suggest a dual role in proliferation and differentiation. Oncogene 1998;17:1027-1037.
28. Lukas J, Bartkova J, Rohde M, Strauss M, and Bartek J: Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity. Mol Cell Biol 1995;15:2600-2611.
29. Bartkova J, Lukas J, Strauss M, and Bartek J: Cell cycle-related variation and tissue-restricted expression of human cyclin D1 protein. J Pathol 1994;172:237-245.
30. Reed AL, Califano J, Cairns P, Westra WH, Jones RM, Koch W, Ahrendt S, Eby Y, Sewel D, Navroz J, Bartek J, and Sidransky D: High frequency of p16 inactivation in head and neck squamous cell carcinoma. Cancer Res 1996;56:3630-3633.
31. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 1995;81:323-330.
32. Ruas M, and Peters G: The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1998;F115-F177.
33. El-Deiry WS, Tokino T, Waldman T, Oliner JD, Velculescu VE, Burrell M, Hill DE, Healy E, Rees JL, Hamilton SR, Kinzler KW, and Vogelstein B: Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res 1995;55:2910-2919.
34. Welcker M, Lukas J, Strauss M, and Bartek J: p21 mutants deficient in inhibiting cyclin-dependent kinases can promote assembly of active cyclin D/Cdk4(6) complexes in human tumor cells. Cancer Res 1998;58:5053-5056.
35. Benedict WE, Lerner SP, Zhou J, Shen X, Tokunaga H, and Czerniak B: Level of retinoblastoma protein expression correlates with p16 status in bladder cancer. Oncogene 1998;18:1197-1203.
36. Franklin DS, Godfrey VL, Lee H, Kovalev GI, Schoonhoven R, Chen-Kiang S, Su L, and Xiong Y: CDK inhibitors p18INK4C and p27Kip1 mediate two separate pathways to colllaboratively suppress pituitary tumorigenesis. Genes Dev 1998;12:2899-2911.
37. Gemma A, Takenoshita S, Hagiwara K, et al: Molecular analysis of the cyclin-dependent kinase inhibitor genes p15, p16, p18 and p19 in human cancer cell lines. Int J Cancer 1996;68:605-611.